Compare Mondaycom Ltd (MNDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Mondaycom Ltd trades at $73.54 (market cap $3.24B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Mondaycom Ltd is far larger — about 2.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| MNDY | RXRX | |
|---|---|---|
Market Cap | $3.24B | $1.53B |
Sector | Technology | Health |
52-Week High | $292.24 | $6.79 |
52-Week Low | $58.81 | $2.84 |
Enterprise Value | $2.21B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $76.75, down 2.47% on the day, reflecting recent bearish pressure. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 versus $0.96 expected. Revenue reached $1.23 billion in 2025 with a net income margin of 9.17%. Technical indicators signal a bearish trend, with the price near key support at $75. The company announced Q2 2026 results will be reported on August 10, 2026 (Business Wire, 2026-07-20).
The investment outlook is mixed: strong analyst consensus (76% buy ratings) and a $115.50 price target suggest significant upside, but technical weakness and a high EV/EBITDA of 97.72 pose risks. Earnings growth and AI integration present opportunities, while market volatility and competitive pressures remain concerns.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
